T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women
- Status
- UNKNOWN
- Phase
- PHASE2
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration
- Status
- COMPLETED
- Phase
- PHASE3
Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
- Status
- COMPLETED
- Phase
- PHASE3
Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- NA